Medtronic (NYSE:MDT) announced today that the FDA cleared two of its AccuRhythm AI algorithms for use with the Linq II ICM.
Fridley, Minn.-based Medtronic’s AccuRhythm AI applies artificial intelligence to heart rhythm event data collected by the Linq II insertable cardiac monitor (ICM) in an effort to improve the information provided to physicians for better diagnoses and treatments for abnormal heart rhythms, according to a news release.
The company will present data on the AccuRhythm algorithms for the Linq II ICM at Heart Rhythm 2021 this week.
Medtronic said the now-cleared, cloud-based AccuRhythm algorithms address the two most common ICM false alerts: Afib and asystole. The Afib algorithm reduced false alerts by 74.1% and preserved 99.3% of true Afib alerts, the company noted, while the “pause” algorithm for asystole reduced false pause alerts by 97.4% and preserved 100% of true pause alerts.
“Applying AccuRhythm AI to Linq II data is a significant ICM innovation, enabling us to reduce clinical inefficiencies resulting from false alerts, and help physicians better identify and focus on the actionable data they need to treat their patients,” CMO of Medtronic’s cardiovascular diagnostics and services business Dr. Rob Kowal said in the release.
The company plans to release the AccuRhythm algorithms on the CareLink network later this year to be used by all implanted Linq II devices in the U.S.
“We are excited to integrate AI capabilities to further elevate the accuracy of Linq II ICM – and provide clinicians with greater confidence in patient care decisions,” president of Medtronic’s cardiovascular diagnostics and services business Julie Brewer said. “We look forward to introducing additional diagnostic innovations to advance patient management in the future.”